Lepuxintai Medical Technology (Shanghai) Co., Ltd. is committed to providing safe, effective and innovative medical solutions. It is a pioneer in the structural heart disease interventional medical device industry in China and a large-scale domestic supplier of congenital heart disease blocking devices. Focus on R&D, production and marketing of medical interventional devices for structural heart disease. Currently, there are 50 products on the market and under development. The product line covers the congenital blocker series for interventional treatment of congenital heart disease, the left ventricular occlusion series for the prevention of cardiogenic stroke and the unclosed occlusion of the ovary, etc., and the biological interventional valve series for treatment of valve stenosis and incomplete closure, which can provide a comprehensive solution for structural heart disease interventional treatment. Our products have been sold overseas to 44 countries and regions in Asia, Europe, America and Africa. The company has strong R&D capabilities, has many innovative products with independent intellectual property rights, and is first involved in the research and development of biodegradable technology. In 2009, the “Development and Clinical Application of Interventional Treatment Series Blockers and Related Devices for Interventional Treatment of Defective Congenital Heart Disease” project won the second prize of the National Science and Technology Progress Award. As of October 18, 2022, the company has 232 registered intellectual property rights. In the future, the company will continue to invest in research and development, continuously develop new products and technologies to benefit more patients with structural heart disease and contribute to the cause of human health.